Introduction. The modern mankind carries a huge anthropogenic burden resulted by progressively worsening environmental situation, changed nutrition habits and quality of food, an increase in adverse social factors, that leads to a strong upward trend in the incidence of urolithiasis all over the world, including Russia. These patients’ treatment outcomes are to a large extent determined by a concomitant drug therapy and secondary prophylaxis. In this medical care combination for patients with urolithiasis lithokinetic therapy occupies an important place. The aim of this study was to investigate the efficacy and safety of the Renotinex® terpenes clinical use during lithokinetic therapy in patients with urolithiasis.

Materials and methods. The study included 142 patients undergoing treatment at the State budgetary institution of health care of the Astrakhan region Aleksandro – Mariinsky regional clinical hospital of Astrakhan State Medical University in 2019. The patient group consisted of 65 men and 77 women. Patients included in the study were divided into two equal groups according to the main clinical and diagnostic criteria. Patients from the group I (main group) received the standard lithokinetic therapy and 2 capsules (600 mg) of Renotinex® 3 times a day from the moment of diagnosis to the end of hospital treatment. For patients from the group II (control group) there was no Renotinex® prescribed.

Results. In patients from the group I renal colic was recorded in 38% of cases, among patients from the control group, renal colic occurred in 91% of cases and was usually recurrent and more challenging to manage. In patients receiving Renotinex® spontaneously passing urinary stone was noted in 76.4% of cases; in the control group, only 34.6% of cases were found to have a similar effect. A complete elimination of the urinary tract stones, as the most optimal result, was achieved in 76.4% of cases in the first group and in 25.3% cases in the control group.

Conclusions. This study demonstrates the high efficacy of the Renotinex® use for lithokinetic therapy in case of primary or residual kidney and ureter stones, regardless of their chemical composition.

Conflict of interest. The authors declare no conflict of interest